ArticleHepatology (Baltimore, Md.)2026
Gut-to-bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders.
Article in Hepatology (Baltimore, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A guide for establishing patient-derived organoids from bile samples obtained during endoscopic procedures and performing gene expression knockdown.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsDuring bile acid (BA) intestinal transit, microbially amidated BAs (MABAs) are produced. This study investigated their cholephilic behavior and their presence in the bile of patients with hepatopancreatobiliary diseases. APPROACH AND
resultsBile samples were collected during surgical or endoscopic procedures and analyzed using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), with cholic acid (CA) and chenodeoxycholic acid (CDCA) chemically amidated with leucine (Leu), phenylalanine (Phe), or tyrosine (Tyr) as standards. Gut-to-bile transfer was investigated in cellular and animal models.MABAs (Leu>Phe>Tyr) were detected (<1 µM) in the bile of ≈50% of patients with hepatopancreatobiliary disorders. Their levels were positively correlated with total BA concentrations and inversely correlated with the proportion of major conjugated BAs, but not with age, fat-soluble vitamin levels, or disease outcomes. Oral gavage of D - and L -enantiomers of Tyr-CA in mice resulted in intestinal hydrolysis and limited access of L -Tyr-CA to the enterohepatic circulation. In rats, the intravenous injection of glycocholic acid (GCA) and MABAs resulted in similarly rapid biliary outputs. The time course of biliary secretion after infusing MABAs and GCA into the microbiota-free rat ileum in situ was also similar. Docking studies predicted the interaction of BA transporters and MABAs with binding energies comparable to those of taurocholic acid (TCA) and GCA. In cells expressing BA transporters, MABA uptake was efficient (NTCP>ASBT>OATP1B3) and inhibitable by TCA.
conclusionsLike major conjugated BAs, MABAs are transferred from the gut, where they are produced, to the bile of patients with hepatopancreatobiliary diseases, suggesting gut dysbiosis that favors species generating these compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.